16 September 2022 - - Tibsovo Now Available from Onco360 for the Treatment of Adult Patients with IDH1-mutant Acute Myeloid Leukemia or Previously Treated, IDH1-mutant Metastatic Cholangiocarcinoma

US-based specialty pharmacy Onco360 has been selected by US-based Servier Pharmaceuticals to be a specialty pharmacy partner for Tibsovo (ivosidenib), the company said.

Tibsovo is an isocitrate dehydrogenase-1 inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with newly diagnosed acute myeloid leukemia in combination with azacitidine or as monotherapy in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, relapsed or refractory AML, or locally advanced or metastatic cholangiocarcinoma that has been previously treated.

According to the National Cancer Institute's Surveillance, Epidemiology, and End Results program, it is estimated that 20,050 new cases of AML will be diagnosed in 2022 in the United States with a corresponding 11,540 deaths in 2022. Approximately 6-9% of AML cases are found to have IDH1 mutations.

The median age at the time of initial AML diagnosis is 68 years. The five-year overall survival for AML patients is only 30.5%.

According to the American Cancer Society, approximately 8,000 patients are diagnosed with cholangiocarcinoma, a bile duct cancer, on an annual basis in the United States.

Approximately 13% of cholangiocarcinoma cases are found to have IDH1 mutations.

The average age at the time of initial cholangiocarcinoma diagnosis is 70-72 years old dependent upon tumor location.

The five-year overall survival for cholangiocarcinoma patients, regardless of cancer stage, is only 9-10% dependent upon tumor location.

Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company.

Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers.

It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies.

Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corp., a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States.